A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment

Trial Profile

A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Disseminated intravascular coagulation; Embolism and thrombosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Asahi Kasei
  • Most Recent Events

    • 23 Feb 2017 Results published in the Thrombosis and Haemostasis Journal.
    • 13 Feb 2017 Status changed from recruiting to completed.
    • 02 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top